Clinical trials: Dry Macular Degeneration
Dry Age-related Macular Degeneration
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- NCT04566445
- Testing
- GT005
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 255 people
- Sponsor
- Gyroscope Therapeutics Limited
Macular Degeneration, Age Related
Evaluating Metabolic Changes Induced by PhotoBioModulation Through Spectrally Resolved Autofluorescence in Dry Age-Related Macular Degeneration Patients
The best treatment to prevent the evolution of early and intermediate forms of dAMD to atrophic degeneration is PhotoBioModulation (PBM).
- Trial name
- PBM-dAMD (NCT06582511)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Francesco Bandello
Age-Related Macular Degeneration
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is the main reason older people lose their vision. It affects the macula, the center of the retina needed for sharp, clear vision.
- Trial name
- NCT02564978
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Eye Institute (NEI)
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
- Trial name
- ARCHER II (NCT06510816)
- Testing
- Vonaprument
- Where
- 132 sites in United States, Australia and 12 more
- Volunteers
- 659 people
- Sponsor
- Annexon, Inc.
Age-Related Macular Degeneration, Macular Degeneration, Age-Related
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients…
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
- Trial name
- METforMIN (NCT02684578)
- Testing
- Metformin
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Francisco
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.
Geographic Atrophy
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
Safety Assessment of APL-2 in Patients with Geographic Atrophy
- Trial name
- NCT03777332
- Testing
- PEGCETACOPLAN (APL-2)
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Macular Degeneration, Senile, Laser Burn of Retina
Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD.
- Conditions
- Macular Degeneration, Senile, Laser Burn of Retina, Macular Degeneration Intermediate, Macular Degeneration, Dry
- Trial name
- PASCAL-RPD (NCT04847635)
- Testing
- Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale San Raffaele
Dry AMD, Stargardt Disease 1
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease
Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.
- Trial name
- MADEOS (NCT03297515)
- Testing
- Madeos
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- Ophthalmos Research and Education Institute
Stargardts, Retinitis Pigmentosa
High Resolution Retinal Imaging
Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disease.
- Conditions
- Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia
- Trial name
- AOSLO (NCT01866371)
- Testing
- Retinal imaging
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dry Age-related Macular Degeneration
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
The purpose of this study is to determine the pharmacodynamics of ocular blood flow measurements with multiple drop unoprostone isopropyl administration versus placebo in subjects with dry age-related macular degeneration (AMD).
- Trial name
- NCT01379560
- Testing
- unoprostone isopropyl
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Sucampo Pharma Americas, LLC
Age-Related Macular Degeneration
A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
The safety and comfort of repeated administrations of a topically-administered ophthalmic formulation of MC-1101 will be established through investigator assessments and subject reporting over a 3 day period.
- Trial name
- NCT01013376
- Testing
- MC-1101, Vehicle
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MacuCLEAR, Inc.
Dry Age-related Macular Degeneration, Macular Degeneration
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
An observational study to evaluate the natural progression of dry AMD in genetically defined subjects
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Trial name
- NCT03894020
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 83 people
- Sponsor
- Gyroscope Therapeutics Limited
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy…
- Trial name
- CHROMA (NCT02247479)
- Testing
- Lampalizumab
- Where
- 145 sites in United States, Argentina and 17 more
- Volunteers
- 906 people
- Sponsor
- Hoffmann-La Roche
Dry Age-related Macular Degeneration
Observational Study of Vision Improvement in Late Stage Dry AMD Patients
The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device.
- Trial name
- NCT04349254
- Testing
- Corneal treatment by a low vision aid device
- Where
- Canada
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Age-Related Macular Degeneration
Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy.
- Trial name
- COMPLETE (NCT00935883)
- Testing
- Eculizumab, Saline
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Philip J. Rosenfeld, MD, PhD